Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Diamedica Therapeutics Inc (DMAC)

Diamedica Therapeutics Inc (DMAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA Business Wire - Thu Dec 18, 7:45AM CST

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS),...

DMAC : 8.23 (-2.83%)
Medical Laboratory by Gorodenkoff via Shutterstock
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double Barchart - Thu Nov 20, 12:50PM CST

What makes analysts so bullish about these three names from the sector?

MEHCQ : 3.5000 (-2.78%)
GHRS : 12.60 (-1.45%)
TYRA : 25.96 (-0.31%)
DMAC : 8.23 (-2.83%)
XBI : 124.98 (-1.05%)
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights Business Wire - Wed Nov 12, 3:30PM CST

Preeclampsia Phase 2 IST Trial: Part 1a Dose Escalation Cohort Complete with Expansion Cohort Now Enrolling; Screening for Part 3, Fetal Growth Restriction Cohort, Expected to Start in Coming Weeks ...

DMAC : 8.23 (-2.83%)
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London Business Wire - Mon Nov 10, 7:15AM CST

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today...

DMAC : 8.23 (-2.83%)
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025 Business Wire - Thu Nov 6, 3:15PM CST

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its third...

DMAC : 8.23 (-2.83%)
Medical research and development by Gorodenkoff via Shutterstock
Why Wall Street Experts Believe This Biotech Stock Represents a Major Opportunity Barchart Impact - Tue Nov 4, 8:33AM CST

Following a bullish initiation report by TD Cowen, DiaMedica Therapeutics (DMAC) is trading higher as analysts express high conviction in its breakthrough drug candidate, DM199, which showed

DMAC : 8.23 (-2.83%)
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Mon Sep 29, 3:15PM CDT

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today...

DMAC : 8.23 (-2.83%)
Medical Laboratory by Gorodenkoff via Shutterstock
This Hidden Gem Biotech is the Only Small-Cap Among Billionaire Investor Leon Cooperman's Top Market-Beating Picks Barchart Impact - Tue Sep 9, 11:16AM CDT

DiaMedica Therapeutics stands out in Leon Cooperman's portfolio as his only small-cap and only biotech stock, which, along with a strong year-to-date return, signals his confidence in its pot

COOP : 210.79 (-2.77%)
MIR : 23.75 (-0.92%)
DMAC : 8.23 (-2.83%)
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences Business Wire - Fri Sep 5, 7:30AM CDT

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, today...

DMAC : 8.23 (-2.83%)
DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference Business Wire - Tue Sep 2, 7:23AM CDT

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today...

DMAC : 8.23 (-2.83%)

Barchart Exclusives

Tesla + Robinhood + FedEx’s Unusually Active Put Options Could Deliver $Big Income Over the Next 30 Days Barchart - Fri Dec 26, 12:30PM CST
In the past 30 days, Tesla, Robinhood, and FedEx’s unusually active put options generated big income. Looking out 30 days, here’s how the three stocks can keep the income flowing. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot